Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Boland

Showing results (481-490 of 571) with videos related to

Pageof 58
Sort By:
Cancer Medicine|August 29, 2025
Proto-Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal CancerDonghyun Kim, Saima Sharif, Juan Antonio Raygoza Garay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2019
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164Dung T Le, Tae Won Kim, Eric Van Cutsem, et al.
Annals of Surgical Oncology|November 24, 2020
Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic EraRichard J Straker, Yun Song, James Sun, et al.
JAAD International|March 19, 2024
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort studyXue Bai, Aleigha R Lawless, Juliane A Czapla, et al.
Nature Communications|August 10, 2020
Reversal of pre-existing NGFR-driven tumor and immune therapy resistanceJulia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.
Nature Communications|February 7, 2023
Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistanceJulia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.
Biorxiv : the Preprint Server for Biology|October 2, 2023
Cancer immunotherapy response persists after lymph node resectionHengbo Zhou, Lutz Menzel, James W Baish, et al.
Advanced Biology|March 28, 2022
Understanding Suboptimal Response to Immune Checkpoint InhibitorsMojun Zhu, Henan Zhang, Katrina S Pedersen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2012
Activation of PI3K signaling in Merkel cell carcinomaValentina Nardi, Youngchul Song, Juan A Santamaria-Barria, et al.
Nature Communications|April 7, 2022
STAG2 regulates interferon signaling in melanoma via enhancer loop reprogrammingZhaowei Chu, Lei Gu, Yeguang Hu, et al.
Pageof 58

Showing results (481-490 of 571) with videos related to

Sort By:
Pageof 58
Cancer Medicine|August 29, 2025
Proto-Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal CancerDonghyun Kim, Saima Sharif, Juan Antonio Raygoza Garay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2019
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164Dung T Le, Tae Won Kim, Eric Van Cutsem, et al.
Annals of Surgical Oncology|November 24, 2020
Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic EraRichard J Straker, Yun Song, James Sun, et al.
JAAD International|March 19, 2024
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort studyXue Bai, Aleigha R Lawless, Juliane A Czapla, et al.
Nature Communications|August 10, 2020
Reversal of pre-existing NGFR-driven tumor and immune therapy resistanceJulia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.
Nature Communications|February 7, 2023
Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistanceJulia Boshuizen, David W Vredevoogd, Oscar Krijgsman, et al.
Biorxiv : the Preprint Server for Biology|October 2, 2023
Cancer immunotherapy response persists after lymph node resectionHengbo Zhou, Lutz Menzel, James W Baish, et al.
Advanced Biology|March 28, 2022
Understanding Suboptimal Response to Immune Checkpoint InhibitorsMojun Zhu, Henan Zhang, Katrina S Pedersen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2012
Activation of PI3K signaling in Merkel cell carcinomaValentina Nardi, Youngchul Song, Juan A Santamaria-Barria, et al.
Nature Communications|April 7, 2022
STAG2 regulates interferon signaling in melanoma via enhancer loop reprogrammingZhaowei Chu, Lei Gu, Yeguang Hu, et al.
Pageof 58